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Background
Cancer development is a multistep process controlled by 
genetic perturbations such as activation of oncogenes or 
silencing of tumour suppressor genes and epigenetic 
events (that is, DNA methylation) occurring within a cell, 
as well as environmental infl uences (for instance, infl am-
mation) [1-4]. Th e cancer stem cell (CSC) theory implies 
that tumours are generated and maintained by a small 
population of cells with both self-renewal and diff eren-
tiation properties that contribute to tumorigenesis and 
cancer cell hetero geneity. CSCs are thought to be present 
in several haematological and solid tumours, including 
breast cancer [5], and to contribute to metastasis 
formation and tumour recurrence after therapy. In fact, 
CSCs seem to be involved in the acquirement of 
resistance to chemo therapy, radiotherapy or targeted 
agents [6-8], and could be the main reason for treatment 
failures. Consequently, a relevant eff ort is required for 
the identifi cation of alternative treatments able to stop 
tumour progression and eradicate cancer.
Articles
Researchers from Struhl’s group at Harvard University 
used the normal immortalized human mammary 
epithelial cell line MCF10A to evaluate the impact of a 
transient activation of the Src oncogene on trans for-
mation [9]. Interestingly, they observed that this single 
event was able to induce an epigenetic switch leading to a 
permanently transformed cell line, which could form 
self-renewing mammospheres containing CSCs. Src 
activation triggered an infl ammatory response via IL-6 
and created a permanent positive feedback loop involving 
NF-κB, Lin-28, Let-7 microRNA and STAT3.
In parallel, Ginestier and colleagues developed a 
strategy to target specifi cally breast CSCs by blocking the 
IL-8 receptor CXCR1 and therefore interfering with 
infl ammation [10]. Indeed, using an inhibitor for CXCR1, 
repertaxin or a blocking antibody, they could deplete the 
CSC population of two breast cancer cell lines in vitro
and could target the CSCs in xenografts in mice, 
retarding tumour growth and reducing metastasis 
formation. Th ey further show that the eff ect of CXCR1 
inhibition is mediated by the FAK/Akt pathway. Notably, 
cells presenting inactivated PTEN or overexpression of 
FAK are resistant to CXCR1 inhibition.
Viewpoint
Th e idea that a normal cell becomes transformed when 
several mutations accumulate permanently in its DNA is 
well accepted. Th e article by Iliopoulos and colleagues, 
however, reports for the fi rst time that a transient event, 
such as activation of Src, is suffi  cient to mediate an 
epigenetic switch that leads to a stable transformed cell 
with self-renewing capacity – suggesting that not only 
mutations in DNA can contribute to cancer [9]. In 
addition, the fact that Src activation triggers an infl am-
matory response opens up the possibility that targeting 
an infl ammatory signal at an earlier step (cytokine 
receptors) or at a later step (microRNA modu lation) may 
be suffi  cient to reduce the CSC population. Th ese are 
major discoveries in the fi eld supported by solid 
experiments; owing to the important implications of 
these fi ndings, however, it becomes essential to transfer 
Struhl’s approach to a mouse model of tumorigenesis.
Abstract
Two recent studies show that epigenetics and 
infl ammation play a relevant role in the regulation of 
transformation and cancer cell self-renewal in breast 
tumours, opening up the possibility that cancer 
progression can be controlled by interfering with 
infl ammation cascades. Struhl’s group showed that 
transient activation of the Src oncoprotein induces 
transformation and self-renewal of immortal cells via 
an epigenetic switch involving NF-κB, Lin28, Let-7 
microRNA and IL-6. Concomitantly, Wicha’s laboratory 
developed a strategy to selectively target cancer stem 
cells, retarding tumour growth and reducing metastasis 
by blocking the IL-8 receptor CXCR1 using either an 
inhibitor, repertaxin or a specifi c blocking antibody.
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Almost as a follow-up to Iliopoulos and colleagues’ 
work, Ginestier and coworkers prove elegantly that 
target ing an infl ammatory signal transduction pathway 
specifi c to CSCs makes reduction of tumour mass 
possible, overcoming the problem of chemoresistance 
[10]. Th e strength of this report is the fact that when 
using a cytotoxic agent alone, such as docetaxel, tumour 
mass is reduced but the CSC population is either not 
aff ected or is even increased. Conversely, repertaxin 
treatment alone or in combination with docetaxel 
signifi cantly reduced the number of CSCs and led to the 
shrinkage of tumour mass by an indirect bystander eff ect 
mediated by FASL/FAS signalling.
Considering that repertaxin has already been used to 
reduce tissue damage after myocardial infarction or 
stroke [11] and that clinical phase I studies demonstrate a 
lack of toxicity for this compound, the use of this CXCR1 
inhibitor in cancer therapy seems very promising. Conse-
quently, it is possible that a synergistic negative eff ect on 
CSC growth or survival can be obtained by targeting 
various infl ammatory signals at the same time, leading to 
a better outcome for several types of cancer.
In conclusion, these two articles present essential work 
for the breast cancer fi eld and bring together three new 
concepts: tumorigenesis can be initiated by one or more 
transient epigenetic events; tumour progression can be 
achieved by the activation of infl ammatory cascades; and 
tumour growth can be arrested or at least kept under 
control by blocking one or more CSC-specifi c 
infl ammatory stimulus.
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